Literature DB >> 16689966

Nephrogenic systemic fibrosis: an emerging threat among renal patients.

Danielle M DeHoratius1, Shawn E Cowper.   

Abstract

Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy, is a scleroderma-like disease of the skin observed in patients with renal insufficiency. Since its recognition in 1997, relatively little has been published in the nephrology literature, despite indications that the disorder is becoming increasingly recognized in the United States and abroad. As nephrology professionals may be the first to encounter newly developing cases of NSF, it becomes imperative that they be able to recognize the symptoms and comorbidities and initiate tests and treatment. To date, the cause of NSF has not been established. Recent observations indicate that specific cells normally involved in wound repair and tissue remodeling may be aberrantly recruited to the skin and soft tissues of NSF patients.

Entities:  

Mesh:

Year:  2006        PMID: 16689966     DOI: 10.1111/j.1525-139X.2006.00152.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  10 in total

1.  Safety of cardiovascular magnetic resonance gadolinium chelates contrast agents in patients with hemoglobinopathies.

Authors:  Antonella Meloni; Brunella Favilli; Vincenzo Positano; Paolo Cianciulli; Aldo Filosa; Antonella Quarta; Domenico D'Ascola; Gennaro Restaino; Massimo Lombardi; Alessia Pepe
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

2.  Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).

Authors:  Tomohiro Sato; Tsutomu Tamada; Shigeru Watanabe; Hirotake Nishimura; Akihiko Kanki; Yasufumi Noda; Atsushi Higaki; Akira Yamamoto; Katsuyoshi Ito
Journal:  Radiol Med       Date:  2015-01-09       Impact factor: 3.469

Review 3.  Nephrogenic systemic fibrosis.

Authors:  Diego R Martin
Journal:  Pediatr Radiol       Date:  2007-12-11

4.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

Review 5.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

Review 6.  Assessment of renal function with dynamic contrast-enhanced MR imaging.

Authors:  Louisa Bokacheva; Henry Rusinek; Jeff L Zhang; Vivian S Lee
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

Review 7.  Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.

Authors:  Gautam Bhave; Julia B Lewis; Sam S Chang
Journal:  J Urol       Date:  2008-07-17       Impact factor: 7.450

Review 8.  Skin problems in chronic kidney disease.

Authors:  Dirk R J Kuypers
Journal:  Nat Clin Pract Nephrol       Date:  2009-02-03

9.  Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.

Authors:  Tsuneo Ishiguchi; Shoki Takahashi
Journal:  Drugs R D       Date:  2010

10.  Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.

Authors:  Laura K Young; Shona Z Matthew; J Graeme Houston
Journal:  Eur Radiol       Date:  2018-10-01       Impact factor: 5.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.